New pyrimidine deoxyribonucleoside analogues, 2'deoxy-2'-methylideneuridine (DMPU), 2'-deoxy-2'methylidenecytidine (DMDC), an~/their 5-substituted derivatives were tested for the anti:herpesvirus activities and anti-proliferative activity. E-5-(2-Bromovin-" yl)uracil derivative (BV-DMDU) and its cytosine congener were synthesized from 1-I3-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil (BV-araU). 5-Bromo, 5-iodo, 5-methyl, and 5-ethyl derivatives of DMDU and BV-DMDU showed activities against herpes simplex virus type 1 (HSV-1) and varicella-zoster virus (VZV). The corresponding DMDC derivatives had no or only weak antiviral activity. Among the 2'-deoxy-2'-methylidene pyrimidine nucleosides, BV-DMDU showed the most potent and selective anti-VZV activity. BV-DMDU was more potent than acyclovir, but less active than BV-araU. BV-DMDU was inactive against human diploid and tumour cells. DMDC and F-DMDC (5-fluoro derivative) were potent inhibitors of HSV-1, herpes simplex virus type 2, VZV, and human cytomegalovirus (HCMV) and also had significant anti-proliferative activity. Their potency against HCMV was better than that of ganciclovir and araC. Some DMDU derivatives also showed anti-HCMV activity, but they had antiproliferative activity. The anti-HCMV activity of these DMDC and DMDU compounds was generally more potent than those against HSV-1 and VZV thereof, suggesting the participation of cellular kinase in their antiviral action.
Introduction 2'-Deoxy-2'-methylidenecytidine (DMDC) is a new class of 2'-deoxycytidine analogues with anti-neoplastic activity (Takenuki et sl., 1988) . However, unlike 1-I3-D-arabinofuranosylcytosine (araC) , DMDC is also active against several solid tumour cell-lines as well as leukaemia cells, and is resistant to cytidine deaminase. Its unique in vivo anti-tumour properties including activity against human lung cancer xenografts in nude mice were demonstrated previously (Yamagami et st., 1991) . Baker and co-workers (Baker et aI., 1991) reported a potent inhibition of ribonucleotide reductase by DMDC 5'-diphosphate. We have also reported the synthesis and in vitro anti-tumour activity of 5-substituted derivatives of DMDC and their uracil congeners (Matsuda et aI., 1991) . With the exception of DMDC and its 5-fluoro derivative (F-DMDC),none ofthese derivatives showed significant activity against murine leukaemia. In this paper we describe the synthesis of new E-5-(2-bromovinyl) derivatives of 2'-deoxy-2'-methylideneuridine (DMDU) and DMDC (BV-DMDU and BV-DMDC, respectively; structures are given in Fig. 1) ,and the antiviral activities of the series of 2' -deoxy-2'-methylidene nucleosides against human herpesviruses; herpes simplex virus types 1 and 2 (HSV-1 and HSV-2), varicellazoster virus (VZV), and human cytomegalovirus (HCMV), and anti-proliferative activity against human embryonic lung fibroblast cells (HEL cells) and leukaemia cells.
Results

Synthesis of BV-DMDU and BV-DMDC
The method for synthesis of 5-substituted DMDC and DMDU derivatives from uridine described previously (Matsuda et aI., 1991) was modified for the synthesis of BV-DMDU and BV-DMDC by using 1-I3-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil (BV-araU) as a starting material (Fig. 2) . The original method for the synthesis of BV-araU (Sakata et al., 1980) was improved: 1-I3-D-arabinofuranosyl-E-5-(2-carboxyvinyl)uracil (CAV-araU) was obtained from 2' ,3' ,5' -tri-O-acetyl-1-I3-D-arabinofuranosyl-5-iodouracil (Lin et aI., 1983 ) by a palladium-catalyzed coupling reaction (Bergstrom et aI., 1978) with methyl acrylate and subsequent hydrolysis. CAV-araU was converted into BV-araU with N-bromosuccinimide by the procedure of Ashwell and co-workers (Ashwell et al., 1987) with minor modifications.
BV-araU was converted into 3',5'-O-tetraisopropyldisiloxane-t ,3-diyl (TIPDS) derivative. {2'S)-hydroxy group by a combination of CrOs: pyridine: acetic anhydride complex and powdered molecular sieves 4A gave the 2'-keto nucleoside, which was then converted into the corresponding 2'-deoxy-2'methylidene derivative with methylenetriphenylphosphorane from methyltriphenylphosphonium bromide with sodium 2-methyl-2-butoxide (Samano et al., 1991) . Deprotection of this compound with tetrabutylammonium fluoride (TBAF) yielded BV-DMDU. BV-D.MDC was obtained from the TIPDS-protected BV-DMDU derivative via its 2,4,6-triisopropylbenzenesulfonyl (TPS) derivative followed by treatment with NH 40H (Sekine, 1989) . Removal of the TIPDS group with TBAF furnished BV-DMDC.
Anti-herpesvirus and anti-proliferative activities
The antiviral activities of DMDC, DMDU, and their 5-substituted analogues' against human herpesviruses were determined. Reference compounds used were: 1-[3-Darabinofuranosyluracil (araU) and araC (structure-related compounds), acyclovir (an anti-HSV drug), BV-araU (a potent anti-VZV compound), and ganciclovir (an anti-HCMV agent). Results of typical plaque inhibition test for Table 1 shows antiviral and anti-proliferative activities of the test compounds. DMDC and F-DMDC were almost as active as acyclovir against HSV-1 and HSV-2. BV-DMDU also had significant anti-HSV-1 activity, but was very weakly active against HSV-2. 5-Chloro, 5-bromo, 5-iodo, 5-methyl, and 5-ethyl derivatives of DMDU (CI-DMDU, Br-DMDU, I-DMDU, Me-DMDU, and Et-DMDU, respectively) showed marked to moderate activity against HSV-1 and HSV-2, while the corresponding DMDC derivatives (CI-DMDC, Br-DMDC, I-DMDC, Me-DMDC, and Et-DMDC, respectively) and BV-DMDC had only weak or no anti-HSV activity. The marked anti-HSV-1 activity of DMDC, F-DMDC, Br-DMDU, and I-DMDU was demonstrated by a plaque reduction method (data not shown). DMDU and its 5-fluoro derivative (F-DMDU) were inactive. The 5-Ethynyl derivative of DMDU (Ethynyl-DMDU) had only weak anti-HSV activities.
Except Br-DMDU and Et-DMDU, methylidene nucleosides were also active against VZV having significant anti-HSV-1 activity. BV-DMDU showed the most potent anti-VZV activity among the methylidene nucleosides. BV-DMDU was more potent against VZV than acyclovir and was as potent as araC, but less active than BV-araU. i I Ill: DNA synthesis. From the chemical structural point of view, 5-substituted DMDU derivatives are also expected to a exhibit anti-herpesvirus activity as the thymidine analogue. Indeed, anti-herpesvirus activities of DMDUderivatives were marked to moderate. On the other hand, activities of the corresponding DMDC derivatives were only weak or inactive. Since DMDC is resistant to cytidine:deoxycytidine deaminase (Takenuki et al., 1988; Lin et al., 1991) , the difference between DMDU and DMDC derivatives in the antiviral activity seems to be due to difference in the susceptibility to viral TK. BV-DMDU, like BVDU and BV-araU, was selectively active against HSV-1 and VZV. Among 2'-deoxy-2'methylidene pyrimidine nucleosides BV-DMDU was the most potent against VZV. Probably, the E-5-(2-bromovinyl)-uracil base is involved in the high anti-VZV potency. (±)-(1 ,2,3)-1-[2,3-Bis(hydroxymethyl)-cyclobutyl]-E-5-(2bromovinyl)uracil was also selectively active against VZV (R. Zahler et al., personal communication). In contrast, Br-DMDU, CI-DMDU, and Me-DMDU were active against A number of 5-substituted derivatives of deoxyuridine and araU are known to have potent and selective antiviral activity against HSV and VZV. 1-[3-D-Arabinofuranosylthymine (Aswell et al., 1977) and 5-(2-chloroethyl)-2'deoxyuridine (DeClercq and Rozenwirth, 1985) are potent against HSV. BV-araU (Machida et al., 1981; Machida, 1986a ) and E-5-(2-bromovinyl}-2'-deoxyuridine (BVDU; De Clercq et al., 1979) are potent against HSV-1 and VZV. These compounds act as thymidine analogues. Their activity is related to the broad substrate specificity of herpesvirus-induced thymidine kinase (TK) (Jamieson et al., 1974) , which phosphorylates these analogues in the infected cells. The phosphorylated analogues inhibit viral Discussion DMDU derivatives, except 5-fluoro derivatives, were more potent than the corresponding DMDC derivatives against VZV and HSV-1. DMDC and F-DMDC had marked anti-HCMV activity, which was more potent than that of araC and ganciclovir. Br-DMDU, CI-DMDU, and Me-DMDU showed moderate anti-HCMV potency. Moreover, the anti-HCMV potencies of DMDC,~;'.DMDC, and the three DMDU analogues were higher than or almost comparable to their anti-HSV-1 or anti-VZV potencies.
DMDC and F-DMDC had potent anti-proliferative activity against both CCRF-HSB-2 and HEL cells. The activity was much higher than that against murine L1210 leukaemia cell growth previously reported . Br-DMDU, CI-DMDU, and Me-DMDU also showed anti-proliferative activity, though the activity against L1210 cells was not significant (Matsuda et aI., 1991) . Thus, all 2'-deoxy-2'-methylidene nucleosides exhibiting anti-HCMV potency showed anti-proliferative activity against HEL and CCRF-HSB-2 cells. Other 5-substituted DMDU and DMDC derivatives including BV-DMDU showed no anti-proliferative activity up to 100 /Lg ml". The data indicate that anti-herpesvirus action of BV-DMDU is highly selective, while selectivity of the action of Br-DMDU, CI-DMDU, and Me-DMDU is low. Table 1 . In vitro anti-herpesvirus activities and anti-proliferative activity of 5-substituted 2'-deoxy-2'-methYlidene pyrimidine nucleosides. 1050 for cell Antiviral activities (ED50; fLg ml") growth (fL9 ml-l )C HCMV, which lacks viral TK. Their anti-HCMV activity was more marked than or almost comparable to their anti-HSV-1 or VZV activity. Therefore, it is suggested that cellular kinase participates in their anti-herpesvirus action. DMDC and F-DMDC were markedly potent against HCMV as well as HSV-1, HSV-2, and VZV. Lin and co-workers (Lin et al., 1991) reported moderate to sigificant activity of these two compounds against HSV-1 and HSV-2. Since Shigeta and co-workers (Shigeta et aI., 1991) reported that araC was the most potent anti-HCMV agent among nucleoside analogues, it is especially noteworthy that anti-HCMV activity of DMDC and F-DMDC was more potent than that of araC. However, they had marked anti-proliferative activity and their antiviral action is not selective. Yamagami and co-workers (Yamagamiet sl., 1991) showed that these compounds acted as the deoxycytidine analogue. The mode of antiviral action seems to be different from that of the DMDU derivatives and the seleptive thymidine analogues described above.
Materials and Experimental procedures: chemistry
Melting points were determined with a Yamato capillary melting point apparatus MP-21 and are uncorrected. 'H (399.65 MHz) and l3C (100040 MHz) nuclear magnetic resonance spectra were obtained with a JEOL GSX-400 spectrometer using tetramethylsilane as internal standard. Mass spectra (EI) were obtained with JMS FX-500 mass spectrometer. Ultraviolet absorption spectra were measured with a Shimadzu UV-160A spectrophotometer. Column chromatography was performed on Merck Kieselgel 60.
Compounds
All DMDC and DMDU analogues, except BV-DMDU and BV-OMDC were prepared as described previously (Matsuda et el., 1991) . AraU, araC, acyclovir, and ganciclovir were synthesized in the Research Laboratories of Yamasa Shoyu Co., Ltd.
1-{3-D-Arabinofuranosyl-E-5-(2-carboxyvinyljuracil (18)
A mixture of 2' ,3' ,5' -tri-O-acetyl-1-[3-D-arabinofuranosyl-5iodouracil (421g, 0.85 mol), methyl acrylate (300ml, 3.33 mol), palladium acetate (19.1g, 0.085 mol), triphenylphosphine (22.5g, 0.085 mol),and triethylamine (150ml, 1.08 mol) in tetrahydrofuran (THF)(1360ml) was heated under reflux for 3 h with stirring. After cooling, CHCI 3 (1500ml) was added to the reaction mixture, and filtered. The filtrate was concentrated in vacuo. The residue was suspended in ethanol (2000ml), and the mixture was then cooled. The resulting precipitate was collected by filtration, and crystallized from ethanol to afford 2' ,3' ,5' -tri-O-acetyl-1-[3-D-arabinofuranosyl-E-5-(2-carbomethoxyvinyl)uracil (213g, 55%). This compound (10g, 22.0 mmol) was dissolved in 0.1 N NaOH (2500ml), and stirred for 4h. The reaction mixture was concentrated to 250ml after neutralizing with 6N HCI, and then acidified and kept at 4°C overnight. The resulting precipitate was collected by filtration and crystallized from water to afford 18 (6.0g, 87%): 
1-{3-D-Arabinofuranosyl-E-5-(2-bromovinyljuracil (19)
N-Bromosuccinimide (15.6g, 87.6 mrnol) was added in a small portion to a stirred suspension of 18 (25.0g, 79.6 mmol) in 100ml of dimethyl formamide containing NaOAc (7.83g, 95.5 mmol) at about 23°C. The mixture was stirred for 30 min. This solution was diluted with water to 2600 rnl, passed through a high porous resin column (Oiaion HP-20, 650ml), and th~f1 eluted with aq, ethanol (10-15%). The eluate was concentratedto 250 ml and kept at 4°C overnight. The precipitate was collected by filtration and suspended into Water (170 ml). The mixture was adjusted to pH 11.5 by the dropwise addition of 2 N NaOH. After decolourization with activated charcoal, the solution was adjusted to pH 4.5 with 6 N HCI and kept at 4°C overnight. The precipitate was collected by filtration and crystallized from water to yield 19 (17. 74.9, 75.1, 84.7, 85.3, 105.9, 108.1, 130.3, 149.1, 161.7; MS(EI) m/z 350, 348 (M+) . Anal Cal cd for C11H1aN20aBr, C; 37.84, H; 3.75, N; 8.02, Found C; 37.94, H; 3.56, N; A mixture of BV-araU (19; 3.49 g, 10 mmol) and 1,3-dichloro-1,1,3,3-tetraisopropyldisiloxane (TIPOSCb, 3.49ml, 10 mmol) in pyridine (50 ml) was stirred at about 23°C for 13 h. The solvent was removed in vacuo. The residue was dissolved in ethyl acetate (30ml), washed with water (20ml x 2); the organic phase Was dried (Na2S04), and the solvent was evaporated. The residue Was triturated with 90% aq, ethanol and then allowed to stand at 4°C overnight. The precipitate was collected by filtration to give 20 (4.45g, 75%): mp 102-104°C; 1H-NMR(OMSO-d a) S, ppm 1. 01-1.10 (28H, m, lsopropylj, 3.72-4.31 (5H, rn, H-2', 3',4', 5'ab) , 5.82 (1H, d, J = 5.9Hz, 2'-OH), 6.03 (1H, d, J = 6.4Hz, H-1'), 6.72 (1H, d, J = 13.7 Hz.vlnyltc-l-l), 7.26 (1H, d, J = 13.7Hz, vinylic-H), 7.49 (1H, s, H-6), 11.65 (1H, s, 3-NH); MS(EI) rn/z 592, 590 (M+). Anal Calcd for C2aHa9N207BrSi2, C; 46.69, H; 6.64, N; 4.73, Found C; 46.63, H; 6.63, N; 5.01. In vitro anti-herpesviruses of DMDC derivatives 15 1- [3, Pyridine (4.15 ml, 5.13 mmol) was added to a stirred cold suspension of CrOa (2.57 g, 25.7 mmol) and powdered molecular sieves 4A (3.85g) in CH 2CI2 (25ml). After stirring for 1 h, acetic anhydride (2.55ml, 27.0 mmol) and 20 (3.04g, 5.14 mmol) in CH 2CI2 (10 ml) were added. The mixture was stirred at about 23°C for 1 h. The reaction mixture was poured into ethyl acetate (350ml), and the solution was passed through a silica gel pad (50 g). The precipitated solids were washed with ethyl acetate (100ml) and combined filtrates were washed with saturated aq. NaHCO a (50ml) and brine (50ml). The organic phase was dried (Na2S04) and filtered. The filtrate was evaporated to dryness. The residue was co-evaporated with toluene (50ml) to yield 21 (2.9g, 96%) as a gum, which was used directly for the next preparation without further purification: IR(KBr) 1786cm-1 (2'-keto); 1H_ NMR(DMSO-d a) S, ppm 0.99-1.10 (28H, rn, isopropyl) ; 48.20, H; 6.40, N; 4.61, Found C; 47.92, H; 6.39, N; 4 .61.
1-[2-Deoxy
To a suspension of methyltriphenylphosphonium bromide (4.0g, 11.2 mmol) in THF (17 ml), 2-methyl-2-butanol (1.2 rnl, 12 mmol) and NaH (492 mg, 60% dispersion in mineral oil, 12.3 mmol) were added, and the mixture was stirred for 2 h under argon. Compound 21 (2.91 g, 4.94 mmol) in THF (15 ml) was added to the resulting yellow suspension. The mixture was stirred at about 23°C for 16h, diluted with ethyl acetate (30ml), and quenched with saturated aq. NH 4CI (15 ml). The organic phase was washed with brine (15 ml), dried (Na2S04), and evaporated to dryness. The residue was chromatographed on a silica gel column (Si0 2, 1OOg,n-hexane/ethyl acetate, 2: 1, vlv) to afford 22 (2.28g, 79%) as a foam: 1H-NMR(DMSO-d a) S, ppm 1. rn, isopropyl), 3.71 (1H, rn, 4.00 (2H, m, b), 4.96 (1H, d, J = 7.8Hz, rn, 6.32 (1H, d , J = 1.5Hz, H-1 '), 6.42 (1H, d, J = 13.7 Hz, vinylic-H), 7.28 (1H, d, J = 13.7 Hz, vinylic-H), 7.65 (1H, s, H-6), 11.69 (1H, s, 3-NH). MS(EI) mlz 588, 586 (M+). Anal Calcd for C24Ha9N20aBrSi2' C; 49.05, H; 6.67, N; 4.77, Found C; 48.92, H; 6.64, N; To a solution of 22(299mg, 0.51 mmol) inTHF(10ml), TBAF (1Min THF, 1 ml) was added. The mixture was stirred for 30 min, and the solvent was evaporated invacuo, and the residue was chromategraphed on a silica gel column (Si0 2, 40g, 10% MeOH-CHCIa) to afford 9 as a foam, which was crystallized from ethanol: yield 142mg (81%); mp 177-179°C (dec.); UV(H 20) A m ax 250nm (E 15000), 292nm (E 10500), Amin 272nm (E 8100); 1H-NMR(OMSOda)S, ppm 3. 58-3.72 (3H, m, H-4', 5'a,b) , 4.53(1H, dd, J = 6.8Hz, 2.0Hz, upon addition of 0 20, H-3'), 5.03 (1H, t, J = 5.4Hz, 5'-OH), 5. 30-5.40 (2H, rn, H-2'1, 6.45 (1H, d, J = 2.0 Hz, H-1 '), 6.87 (1H, d, J = 13.7Hz, vinylic-H), 7.26 (1H, d, J = 13.7Hz, vinylic-H), 7.80 (1H, s, H-6), 11.69 (1 H, s, 3-NH); MS(EI)m/z 346, 344 (M+). Anal Calcd for C12H13N20sBr, C; 41.82, H; 3.67, N; 7.95, Found C; 41.76, H; 3.80, N; 2,4,6-Triisopropylbenzenesufonyl chloride (TPS-CI,394mg, 1.30 mmol) was added to a mixture of 22 (597mg, 1.02 mmol), Na2C03 (848mg, 8.0 mmol), tetrabutylammonium bromide (14mg, 0.04 mmol) in CH 2CI 2 (20ml) and H 20 (40ml). The mixture was stirred at about 23°C for 15 h. The organic phase was separated, dried (Na2S04), and filtered. The filtrate was evaporated in vacuo to give crude 23, which was dissolved in a solution of concentrated NH 40H (13ml) and dioxane (40ml). The mixture was stirred for 1 h and evaporated to dryness. The residue was dissolved in THF (10ml), to which TBAF (1 M in THF, 2ml) was added. The mixture was stirred at about 23°C for 30 min. The solvent was concentrated to dryness, and the residue was chromatographed on a silica gel column (Si0 2, 40g, 15% MeOH~CHCIs) to afford 17 ; 40.81, H; 4.28, N; 11.90, Found C; 40.50, H; 41.5, N; 11.62. 
Materials and Experimental procedures: virology
Cells and viruses
HEL cells anathe following virus strains were used: HSV-1 VR-3 strain, HSV-2 MS strain, VZV Oka strain, and HCMV AD 169 strain. The origin of these cells and viruses were described earlier (Machida, 1986b) .
Assay for anti-herpesvirus activities
Antiviral activity against HSV-1 and HSV-2 was examined by a cytopathic-effect (CPE) inhibition method as described earlier (Machida et al., 1981) : HEL cells grown in 96 multi-wells were infected with about 100 plaque forming units (pJ.u.) of HSV. After 30 min of virus absorption, virus inoculum was discarded, and the infected cells were incubated with test compound in serial 0.5 log10dilution in a CO 2-incubator at 37"C for 2 days. The CPE in each well were determined by microscopic examination. The antiviral activity was expressed as ED so at which HSV-induced CPE were suppressed at least 50%.
Anti-VZV activity was determined by the plaque reduction method as described earlier (Machida, 1986a (Machida, , 1986b . Briefly, HEL cells in a 24 multi-well plate were infected with 50-100 pJ.u. of cell-associated VZV. After virus adsorption for 1h, drugs in serial half-log 10 dilutions were added to the infected cultures. The cells were incubated in a CO 2-incubator at 37"C for 4 days, and then stained with 0.5% crystal violet solution. For the anti-HCMV test, HEL cells were infected with cell-free HCMV and incubated with drugs by the same manner. After a 4-day incubation period, the cells were re-fed with fresh medium containing 0.4% methyl cellulose and the same concentration of each drug, and incubation was continued for 3-4 days. The cells were stained with May-Gruenwald's and Giemsa solutions. The number of plaques of VZV or HCMV was counted under a stereoscopic light microscope. The 50% plaque reduction dose was interpolated from the dose-response curve, and defined as ED so.
Anti-proliferative activity test
A cell suspension of human Tvcell acute Iymphoblastoid leukaemia cells, CCRF-HSB-2, containing 1.1 x 10 s cells per ml, was prepared in RPMI 1640 medium supplemented with 10% fetal bovine serum. Cells were incubated with test drug, diluted in serial half-log 10 in the culture medium, in a 5% CO 2-incubator at 37"C. After 4 days of incubation, the number of cells was counted with a Microcell Counter (Sysmex, Type F-300). Inhibition of growth of HEL cells was determined by counting the number of cells. The cells were plated in 60-mm plastic dishes at 2.0 x 10 4 per dish. After 4 h, the cells were re-ted with fresh growth medium containing an appropriate amount of test compound. After 4 days of incubation, cells from duplicate cultures were dispersed by trypsin, and the number of cells was counted under a microscope using a haematocytometer. Inhibition per cent for growth of CCRF-HSB-2 and HEL cells was calculated according to the following formula: Inhibition (%) = ( 1 -6~:::: g~) x 100 Tx: Number of cells at the end of incubation with test drug. C~: Number of Cells at the end of incubation without drug. Co: Number of cells at beginning incubation. The ID so of test compound was determined by interpolation from dose-inhibition response curves.
